Navigation Links
Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
Date:2/22/2009

New procedure could offer a safer, more convenient treatment for spine tumors

LAS VEGAS, Feb. 22 /PRNewswire-USNewswire/ -- For orthopaedic researcher Joyce Keyak, Ph.D., finding ways to battle breast cancer is a personal as well as a professional mission. Her cousin died from the disease several years ago. Dr. Keyak still remembers the incredible pain her cousin experienced when the cancer spread to her spine. A new study released by Dr. Keyak and her colleagues at the University of California, Irvine, shows patients whose breast cancer metastasizes to their spines may have a better option than the usual treatment, which can include up to 10 sessions of radiation therapy. The study looked at alternative -- injecting radioactive bone cement into the vertebral body -- with promising results.

The UCI researchers collaborated with a colleague from St. Jude Heritage Medical Group in Fullerton, Calif., to investigate this technique. Dr. Keyak is presenting the team's findings in the paper "Feasibility of Using Radioactive Bone Cement to Treat Vertebral Metastases" during the 55th Annual Meeting of the Orthopaedic Research Society, Feb. 22-25, 2009, in Las Vegas.

"With further development, this technology may yield a clinically feasible procedure that would eliminate the need for 10 radiation therapy sessions, making it more convenient for the patient," says Dr. Keyak, an associate professor in UCI's department of orthopaedic surgery. "This procedure would also deliver a higher dose to the bone metastases and a lower dose to the spinal cord and other normal tissues than conventional external beam radiation therapy, potentially improving the clinical outcome," she explains. "The negligible dose to the spinal cord would also make it possible to treat recurrent spinal tumors in patients who have already received the maximum allowable radiation dose to the spinal cord."

According to the American Cancer Society, almost 185,000 people in the United States -- mainly women -- were diagnosed with invasive breast cancer in 2008. In addition, a study published in the journal Spine showed that, of those patients whose breast cancer metastasizes, almost 75 percent develop spine tumors.

Spinal metastases can cause pain and vertebral collapse. And, due to the proximity of the spinal cord and nerves, those tumors can lead to serious neurological complications. Conventional treatment often occurs in two phases:

  1. A surgical procedure (vertebroplasty or kyphoplasty) in which bone cement is injected into the body to stabilize the bone
  2. Subsequent external beam radiation therapy (or EBRT) to control tumor growth

The effectiveness of EBRT for spinal metastases is limited because the spinal cord restricts the dose of radiation that can be safely delivered. In addition, EBRT is typically provided in multiple sessions to reduce toxicity to the spinal cord, making treatment inconvenient for the patient.

The therapy investigated by Dr. Keyak and her colleagues would combine the two treatment phases into one procedure by mixing a radioactive compound with the injected cement. A single procedure using this radioactive bone cement would provide structural reinforcement to the bone while simultaneously irradiating the tumor from within (i.e., vertebral brachytherapy). Results of the study showed that a therapeutic dose of radiation would reach the intended bone without undue risk to tissue beyond a certain range (such as the spinal cord).

Once the results are validated, subsequent studies will look at the following:

  • Refining the choice of radioisotope(s), amount of activity and geographic distribution of the cement
  • Sensitivity of the radiation dose distribution to variations in bone size, density and tumor type; differences in bone cement formulations; and other factors associated with a potential clinical application

An abstract of the study is available online at http://www.ors.org/web/Media.asp.

For more information about the Orthopaedic Research Society, visit the ORS Web site (http://www.ors.org/web/about_the_ors/welcome.asp).


'/>"/>
SOURCE Orthopaedic Research Society
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
2. Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
3. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
4. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
5. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
8. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
9. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
10. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
11. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... -- This report provides all the information you require ... activities since 2010. Download the full report: ... and Alliance since 2010 report provides an in-depth insight ... leading life sciences companies. On demand company ... the most up to date deal and company data. ...
(Date:2/28/2017)... Feb. 27, 2017 This report provides all ... its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... , Feb 28, 2017 Research ... Enzyme Supplements Market Forecasts 2014-2025" report to their offering. ... ... USD 1.6 billion by 2025. Growing consumer awareness regarding the ... health is expected to stimulate industry growth over the forecast ...
Breaking Medicine Technology:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Much attention has ... for women who become dependent on opioid painkillers has fallen short. From 1999 until ... to a 237% increase in fatal overdoses in male populations.(1) , The proportion of ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria in plaque ... cleaning, also referred to as a scaling and root planing or SRP, and can ...
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley ... to announce a new informational post on robotic hair transplantation. San Francisco residents ... hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can ...
Breaking Medicine News(10 mins):